PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026
All the vital news, analysis, and commentary curated by our industry experts.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms.
GlobalData estimates the 2016 sales for AD at approximately $3.0B across the 7MM covered in this report.
The AD pipeline activity is strong, with twenty active Phase III (or Phase II/III) pipeline agents, most notable drug classes of which being passive immunotherapies and BACE inhibitors. These late-phase drugs also include those targeted for AD-linked agitation and cognitive impairments. Despite the fierce competition, GlobalData expects AD drug development to continue to see considerable struggles until reliable biomarkers and diagnostics are developed. Nevertheless, the treatment landscape of AD is expected to see a substantial change during the forecast period of 2016-2026.
Overview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
BioArctic NeuroScience AB
Charsire Biotechnology Corp
Kyowa Hakko Kirin
Mediti Pharma Inc
Merck & Co
Metabolic Therapy Inc
Suven Life Sciences
Tetra Discovery Partners
Table of Contents
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Alzheimer’s Market Forecast to See Double-Digit Sales Growth out to 2026
2.2 Allergan, Biogen, and Roche Are Forecast to Lead the AD Market in 2026
2.3 Lack of Treatments and Biomarkers Remain As Key Unmet Needs in the AD Market
2.4 Opportunities Remain for Disease-Modifying and Symptomatic Drugs Entering the AD Market
2.5 Twenty Promising Drugs in Phase II/III or Phase III of Development
2.6 What Do Physicians Think?
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Disease Staging Systems
4.5 Quality of Life
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.4.3 Total Prevalent Cases of AD
5.4.4 Total Prevalent Cases of AD by Severity
5.4.5 Total Prevalent Cases of MCI
5.5 Epidemiological Forecast for AD (2016–2026)
5.5.1 Total Prevalent Cases of AD
5.5.2 Age-Specific Total Prevalent Cases of AD
5.5.3 Sex-Specific Total Prevalent Cases of AD
5.5.4 Total Prevalent Cases of AD by Severity
5.6 Epidemiological Forecast for MCI (2016–2026)
5.6.1 Total Prevalent Cases of MCI
5.6.2 Age-Specific Total Prevalent Cases of MCI
5.6.3 Sex-Specific Total Prevalent Cases of MCI
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of Analysis
5.7.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis Overview
6.1.1 Probable AD Dementia
6.1.2 Preclinical AD
6.2 Treatment Overview
6.3 Clinical Practice
6.3.1 Leading Prescribed Therapies
7 Competitive Assessment
7.2 Product Profiles – Major Brands
7.2.1 Aricept (Donepezil Hydrochloride)
7.2.2 Exelon (Rivastigmine, Rivastigmine tartrate)
7.2.3 Razadyne (Galantamine Hydrobromide)
7.2.4 Namenda (Memantine Hydrochloride)
7.2.5 Namzaric (Memantine and Donepezil Hydrochlorides)
7.3 Other Therapeutic Classes
8 Unmet Needs and Opportunity Assessment
8.2 Drugs with Disease-Modifying Mechanisms of Action
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.3 Diagnosis in the Prodromal or Presymptomatic Stages
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.4 Improved Control of Symptoms
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.5 Easier Access to Treatment
8.5.1 Unmet Need
8.5.2 Gap Analysis
9 Pipeline Assessment
9.2 Clinical Trial Mapping
9.2.1 Clinical Trials by Class
9.3 Promising Drugs in Clinical Development
9.3.1 Biopharmaceutical Products
9.3.5 Flebogamma + Albutein
9.3.7 Small Molecule
9.3.18 TRx-0237 (LMTX)
9.3.23 Other Drugs in Development
10 Current and Future Players
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.8 Eli lilly
10.3.9 Merck & Co.
11 Market Outlook
11.1 Global Markets
11.1.2 Drivers and Barriers – Global Issues
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4.2 Key Events
11.4.3 Drivers and Barriers
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research – KOLs Interviewed for This Report
12.5 Primary Research – Prescriber Survey
12.6 About the Authors
12.6.2 Therapy Area Director
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.